Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Pharmacology and therapeutic potential of interferons.
US court permits generic version of Teva MS drug a year sooner
Heterogeneity of serum gelatinases MMP-2 and MMP-9 isoforms and charge variants.
What Explains Gray Matter Atrophy in Long-standing Multiple Sclerosis?
First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models.
Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging
Daclizumab Therapy for Multiple Sclerosis.
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
A urinary test procedure for identification of cannabidiol in patients undergoing medical therapy with marijuana.
Phase 3 Study of RPC1063 in Relapsing MS
Federation of Clinical Immunology Societies 2012
Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders.
Pharmacokinetics of CAMPATH-1H in BMT patients.
Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations.
Diffusely abnormal white matter in multiple sclerosis: further histologic studies provide evidence for a primary lipid abnormality with neurodegeneration.
Reviewing the Unmet Needs of Patients with Multiple Sclerosis.
Fourth PML Case With Tecfidera in MS Calls for Vigilance
Complexity of trophic factor signaling in experimental autoimmune encephalomyelitis: Differential expression of neurotrophic and gliotrophic factors.
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
Dose comparison trial of sustained-release fampridine in multiple sclerosis.
Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
Translating Fatigue to Human Performance.
The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis.
FDA approval letter for daclizumab for the prophylaxis of acute organ rejection in patients receiving renal transplants
Accentia Biopharmaceuticals Conducts Investigator Meeting in Preparation for New Multiple Sclerosis Drug Study for Cyrevia™

Pages